AN2 Therapeutics Stops Phase 2/3 Epetraborole Trial for MAC Lung Disease
The EBO-301 study is being discontinued following topline results from the phase 2 part of the study in treatment-refractory patients with MAC lung disease.
Tag: MAC mycobacterium avium complex
All
Latest
AN2 Therapeutics Stops Phase 2/3 Epetraborole Trial for MAC Lung Disease
The EBO-301 study is being discontinued following topline results from the phase 2 part of the study in treatment-refractory patients with MAC lung disease.
Read More
Bronchiectasis Questionnaire Reliable for MAC Patients
Researchers presented results at ATS 2024 for three clinical trials related to mycobacterium avium complex disease and pharmacological therapies for COPD.
Read More
Metals in Water Linked to Increased Lung Infections in Cystic Fibrosis
An NIH study found high levels of some minerals and metals in environmental water supplies may increase the risk of nontuberculous mycobacteria pulmonary infections in people with cystic fibrosis.
Read More
CFF Grant to Advance Nitric Oxide Therapy for NTM Pulmonary Disease
Over $2 million in CFF funding will support research into high concentration inhaled nitric oxide for the treatment of Nontuberculous Mycobacteria Pulmonary Disease (NTM).
Read More
Arikayce Added to Standard Therapy Benefitted MAC Lung Patients
The addition of Arikayce to guideline-based therapy (GBT) was superior to GBT alone in patients with refractory Mycobacterium avium complex (MAC) lung disease, according to data presented at ATS 2019.
Read More
Arikayce Nets $21M in First 6 Months Treating MAC Lung Disease
Six months after Insmed Inc launched Arikayce for treatment of Mycobacterium avium complex (MAC) lung disease, the drug has netted $21 million in sales.
Read More
FDA Approves Arikayce for Mycobacterium Avium Complex
The US FDA has approved Arikayce for the treatment of lung disease caused by Mycobacterium avium complex, a type of nontuberculous mycobacteria commonly found in water and soil.
Read More